Amsterdam-based , a joint venture company between and , announced that it has completed a €2M funding round, led by . The funding will propel the development of SERDA’s enzymatic wound debridement product, SN514. With a successful Investigational New Drug (IND) submission, the company is gearing towards commercialisation with a Phase 1 clinical trial underway, followed by a Phase IIa study on burn wounds later this year.
Supported by the US Army’s medical research division, this marks an “important step” in making SERDA’s wound care solutions accessible to those in need. What does SERDA Therapeutics offer? Founded in 2020, SERDA Therapeutics is developing a proprietary product for wound debridement tailored to address severe burn injuries and chronic ulcers, such as pressure ulcers, open leg wounds, and diabetic foot ulcers. Gabor Heltovics, CEO of SERDA, says, “Our mission at SERDA is to revolutionise wound debridement and improve the lives of those suffering from such conditions.
” “Our enzymatic debridement technology is being developed to combine exceptional long-term stability with fast removal of damaged tissue, significantly reducing healing time and discomfort. This approach would not only speed up recovery but also improve the quality of life for patients dealing with chronic conditions and burn injuries.” Millions worldwide endure chronic and burn wounds, worsened by aging and diabetes.
Traditional methods like surgery and enzymatic debridement ar.
